ArticlePloS one2026
Pharmacogenetic strategies to mitigate cisplatin-induced ototoxicity in head and neck cancer: A cost-minimization analysis with the use of GSTP1 c.313A>G genotyping.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCisplatin is a cornerstone agent in the treatment of head and neck squamous cell carcinoma. Nonetheless, cisplatin is associated with significant ototoxicity, leading to substantial irreversible hearing loss. Pharmacogenetic testing offers a potential strategy to identify patients at risk, allowing for personalized treatment plans that could mitigate this adverse event and reduce related costs.
methodsThis study aimed to evaluate the economic impact of pharmacogenomic screening. A cost-minimization analysis was conducted using a decision-analytic model incorporating Bayesian inference through Metropolis-Hastings algorithm. Probabilities of ototoxicity were derived from existing literature. The costs of standard treatment were compared with those of a genotype-guided approach, assessing potential cost savings related to the need for audiological interventions.
resultsIn 250 patients, the genotype-guided approach reduced the incidence of moderate-to-severe ototoxicity from 29% to 18% among low-risk patients while avoiding cisplatin in high-risk individuals. The total savings over 10 years were estimated at US$13,077.73 (Credible Interval US$11,026.07 to US$14,147.61), driven primarily by reduced costs for audiological interventions. The break-even point for cost-effectiveness was achieved when at least 275 patients were tested annually. Sensitivity analyses demonstrated that the cost savings remained robust under variations in patient volume and testing costs.
conclusionsImplementing pharmacogenomic screening in the management of head and neck squamous cell carcinoma patients treated with cisplatin may offer significant economic benefits. Personalized treatment plans based on genetic risk for ototoxicity could potentially not only enhance patient-related outcomes but also contribute to more efficient use of healthcare resources. Prospective, randomized evaluations would be ideal to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.